Australia markets closed

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5800+0.0200 (+1.28%)
At close: 04:00PM EST
1.5800 0.00 (0.00%)
After hours: 07:11PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.5600
Open1.5200
Bid1.5700 x 900
Ask1.6100 x 800
Day's range1.5000 - 1.6295
52-week range1.4900 - 31.2400
Volume201,576
Avg. volume1,832,390
Market cap37.961M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-26.0170
Earnings date18 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.80
  • GlobeNewswire

    Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement

    Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has closed its previously announced definitive agreement to sell securities in a private placement with a leading healthcare inves

  • GlobeNewswire

    Clarus Therapeutics Announces $15 Million Private Placement

    Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor. The gross pr

  • GlobeNewswire

    Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

    JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list these patents in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to seven NORTHBROOK, Ill., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to